Insulet (BSP:P2OD34) Stock Based Compensation: R$412 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:P2OD34 Insulet Corp BSP:P2OD34
62 GF Score
Price R$22.68
GF Value R$66.65
Valuation Significantly Undervalued
View Full Analysis

What is Insulet Stock Based Compensation?

Insulet BSP:P2OD34 62 Stock Based Compensation is R$412 Mil as of Jun. 2026. GuruFocus rates BSP:P2OD34 with a GF Score™ of 62/100 and a GF Value™ of R$66.65 (Significantly Undervalued).

Insulet's Stock Based Compensation for the three months ended in Jun. 2026 was R$100 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 was R$412 Mil.

Insulet Stock Based Compensation Related Terms

Insulet Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Insulet's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Insulet Stock Based Compensation Chart

Insulet Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 194.53 214.54 237.15 422.80 342.07

Insulet Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 41.59 89.56 110.75 111.39 100.43
BSP:P2OD34
62GF Score
Insulet Corp BSP:P2OD34
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Insulet Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$412 Mil.

What does a Stock Based Compensation of R$412 Mil mean?
Insulet (BSP:P2OD34) has a Stock Based Compensation of R$412 Mil as of Jun. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Insulet and its competitors.
Is Insulet's Stock Based Compensation too high?
Insulet's current Stock Based Compensation is R$412 Mil. Overall, Insulet has a GF Score™ of 62/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Insulet's Stock Based Compensation compare to GMED and PEN?
Insulet's Stock Based Compensation of R$412 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Medical Devices & Instruments company?
A good Stock Based Compensation depends on the Medical Devices & Instruments industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Insulet and its competitors. Insulet's current Stock Based Compensation is R$412 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insulet stock overvalued right now?
Based on GuruFocus' analysis, Insulet (BSP:P2OD34) is currently considered Significantly Undervalued. The stock's GF Value™ is R$66.65, compared to a current price of R$22.68 — trading 66% below its estimated fair value. The current Stock Based Compensation is R$412 Mil. Insulet's overall GF Score™ is 62/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Insulet (BSP:P2OD34), the current Stock Based Compensation is R$412 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Insulet (BSP:P2OD34) Overvalued in 2026?

Based on GuruFocus' analysis, Insulet stock appears to be undervalued. The current stock price of R$22.68 is trading 66% below its estimated GF Value™ of R$66.65. GuruFocus considers Insulet to be Significantly Undervalued.

Key valuation signals for BSP:P2OD34:

  • Stock Based Compensation: R$412 Mil
  • GF Value™: R$66.65 vs. price of R$22.68 (66% below fair value)
  • GF Score™: 62/100

No single metric tells the full story. See the BSP:P2OD34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Insulet Business Description

Address 100 Nagog Park, Acton, MA, USA, 01720
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.
62GF Score

Get the complete analysis for BSP:P2OD34

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$22.68
Price
R$66.65
GF Value